NewAmsterdam Regulatory Friday, July 24, 2026 0.00 Neutral

NewAmsterdam, Menarini Receive CHMP Recommendation for Ubeslo and Evlarco

NewAmsterdam and Menarini received a positive CHMP opinion patent dosing options for obicetrapib, pending further regulatory review.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day